Biomimetic hyaluronic acid-stabilized zinc oxide nanoparticles in acne treatment: A preclinical and clinical approach
Journal of Controlled Release · 2025-06 · 382 · 113754
DOI: 10.1016/j.jconrel.2025.113754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-06. Verfasst von Jiaojiao Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China. Hauptthemen laut MEDLINE: Zinc Oxide, Acne Vulgaris, Hyaluronic Acid, Anti-Bacterial Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Acne vulgaris is a common chronic inflammatory skin condition, often caused by C. acnes infection. While ZnO has shown promise as an antibacterial agent in acne treatment, concerns over toxicity and non-selective bacterial killing remain. In this study we developed a hyaluronic acid-stabilized nano‑zinc oxide (HA-ZnO) formulation aimed at enhancing the therapeutic efficacy and safety of ZnO for acne treatment. HA-ZnO was synthesized through biomimetic mineralization. HA-ZnO targeted acne-prone areas, especially sebaceous glands, without skin penetration. HA-ZnO demonstrated selective antibacterial activity against C. acnes, exhibiting a killing efficacy more than 16 times greater than that against S. epidermidis. The HA coating also improved ZnO's stability in acidic conditions, mitigating potential toxicity and side effects. Additionally, the sustained release of Zn2+ promoted cell proliferation and migration, reducing sebum secretion, and exerting anti-inflammatory effects, supporting scar-free acne repair and preventing recurrence. In preclinical models, HA-ZnO outperformed erythromycin ointment in treating acne, with no toxicity observed in zebrafish and HET-CAM. A clinical trial further confirmed its efficacy in reducing acne lesions and redness, with high safety. These results highlight HA-ZnO as a promising therapeutic strategy for acne, combining potent antibacterial and skin-repairing effects with enhanced safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China; Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, China.
- Hunan BeautySci Biotech Co., Ltd, Hunan 410122, China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China; Hunan BeautySci Biotech Co., Ltd, Hunan 410122, China. Electronic address: zhouwenhuyaoji@163.com.
Zitieren
APA
Zhu, J., Wen, T., Ma, Y., Zeng, Q., Li, P., & Zhou, W. (2025). Biomimetic hyaluronic acid-stabilized zinc oxide nanoparticles in acne treatment: A preclinical and clinical approach. Journal of Controlled Release, 382, 113754. https://doi.org/10.1016/j.jconrel.2025.113754
Vancouver
Zhu J, Wen T, Ma Y, Zeng Q, Li P, Zhou W. Biomimetic hyaluronic acid-stabilized zinc oxide nanoparticles in acne treatment: A preclinical and clinical approach. Journal of Controlled Release. 2025;382:113754. doi:10.1016/j.jconrel.2025.113754
BibTeX
@article{Zhu2025,
author = {Zhu, Jiaojiao and Wen, Tiao and Ma, Yunxiao and Zeng, Qingya and Li, Pei and Zhou, Wenhu},
title = {Biomimetic hyaluronic acid-stabilized zinc oxide nanoparticles in acne treatment: A preclinical and clinical approach},
journal = {Journal of Controlled Release},
year = {2025},
volume = {382},
pages = {113754},
doi = {10.1016/j.jconrel.2025.113754}
}
EUVIMED